Yamao Jun-ichi, Kikuchi Eiryo, Matsumoto Masami, Nakayama Masaki, Ann Tatsuichi, Kojima Hideyuki, Mitoro Akira, Yoshida Motoyuki, Yoshikawa Masaaki, Yajima Hiroshi, Miyauchi Yoshizumi, Ono Hiroshi, Akiyama Koichi, Sakurai Goro, Kinoshita Yoshikazu, Haruma Ken, Takakura Yoshinori, Fukui Hiroshi
Third Department of Internal Medicine, Nara Medical University, 840 Shijocho, Kashihara 634-8512, Japan.
J Gastroenterol. 2006 Dec;41(12):1178-85. doi: 10.1007/s00535-006-1952-5. Epub 2007 Feb 6.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are major causes of gastric mucosal lesions. In Japan, histamine-2 receptor antagonists are frequently prescribed, but the literature regarding their efficacy is limited. In this study, we compare the effects of famotidine and rebamipide on NSAID-associated gastric mucosal lesions using upper gastrointestinal endoscopy.
This study examined 112 patients taking NSAIDs for either gastric hemorrhage or erosion. Before treatment, the patients were assessed by endoscopy. Using blind randomization, patients were divided into two groups: group F (famotidine, 20 mg/day) and group R (rebamipide, 300 mg/day). Efficacy was examined 4 weeks later using endoscopy.
After treatment, the Lanza score decreased significantly in group F (P < 0.001) but not in group R (P = 0.478). The change in the Lanza score in group F was significantly greater (P = 0.002) than that in group R.
Famotidine was superior to rebamipide in treating NSAID-associated mucosal lesions.
非甾体抗炎药（NSAIDs）和幽门螺杆菌感染是胃黏膜病变的主要原因。在日本，组胺-2受体拮抗剂的使用很频繁，但关于其疗效的文献有限。在本研究中，我们使用上消化道内镜比较法莫替丁和瑞巴派特对NSAID相关胃黏膜病变的影响。
本研究检查了112例因胃出血或糜烂而服用NSAIDs的患者。治疗前，通过内镜对患者进行评估。采用盲法随机分组，将患者分为两组：F组（法莫替丁，20毫克/天）和R组（瑞巴派特，300毫克/天）。4周后通过内镜检查疗效。
治疗后，F组的兰扎评分显著降低（P < 0.001），而R组未降低（P = 0.478）。F组兰扎评分的变化显著大于R组（P = 0.002）。
在治疗NSAID相关黏膜病变方面，法莫替丁优于瑞巴派特。
Zotero 插件